What is the role of sutimlimab in the treatment of cold agglutinin disease?

Updated: Aug 28, 2018
  • Author: Salman Abdullah Aljubran, MD; Chief Editor: Michael A Kaliner, MD  more...
  • Print
Answer

Sutimlimab (formerly TNT009), a humanized monoclonal antibody directed against complement factor C1s, has been shown in preclinical studies to inhibit the classical complement pathway, which is activated in cold agglutinin disease, [57]  and has entered human trials.68 Clinical trials of sutimlimab are currently recruiting.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!